<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15203">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00193427</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI LUN 76</org_study_id>
    <nct_id>NCT00193427</nct_id>
  </id_info>
  <brief_title>Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Trial of Preoperative (Neo-adjuvant) Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to study the role of docetaxel/gemcitabine, an active and relatively
      non-toxic combination in advanced NSCLC. This study will help to better define optimal
      preoperative regimens for patients with resectable NSCLC. Since both of these drugs are
      potent radio-sensitizers, the concurrent use with radiation therapy at these weekly doses
      may produce not only radio-sensitization, but also considerable antitumor efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon determination of eligibility, patients will receive:

      Pre-operative

        -  Docetaxel

        -  Gemcitabine Post-operative

        -  Docetaxel

        -  Carboplatin

        -  Radiation Therapy

      Patients with stage IB and II NSCLC who achieved clear margins will not receive any further
      therapy. Patients with incomplete resection, resection margins of a T3 tumor that are
      positive or close, stage IIIA AND IIIB NSCLC or disease judged unresectable after
      preoperative chemotherapy will receive postoperative treatment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>A pathological complete response (pCR) was defined as having no residual cancer at the primary site or in regional lymph nodes on pathologic review.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>19 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival was calculated as the elapsed time between the date of study registration and the date of recurrence or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall response rate is the percentage of patients with complete response or partial response per RECIST v.1 Criteria. Complete response (CR) = Disappearance of all target lesions, disappearance of all nontarget lesions for at least 4 weeks. Partial Response (PR) = At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival was calculated as the elapsed time bewteen date of study registration and the date of death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with potentially resectable clinical stage IB, II, and selected III NSCLC received gemcitabine 1000 mg/m2 days 1, 8 and docetaxel 30 mg/m2 days 1, 8 every 21 days for 3 cycles. Patients were restaged after treatment and resected 3-6 weeks later. If patients were inoperable, had incomplete resections or N2 disease, docetaxel 20 mg/m2 and carboplatin AUC = 1.5 weekly x 7 and radiation to 63 Gy was administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>30mg/m2 administered on days 1 and 8, 21-cycle days, 3 cycles</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m2 administered by 30-minute IV infusion on day 1 and 8, 21-cycle days, 3 cycles</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC = 1.5 weekly x 7</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>To 63 Gy</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be included in this study, you must meet the following criteria:

          -  Histologically confirmed non-small cell lung cancer

          -  Must be operable candidate

          -  Clinical stage IB, II, and select III non-small cell lung cancer are eligible

          -  Measurable or evaluable disease

          -  Able to perform activities of daily living with minimal assistance

          -  Must be &gt; 18 years of age

          -  Adequate bone marrow, liver or kidney

          -  No previous chemotherapy or radiation therapy for non-small cell lung cancer

          -  Moderate to severe peripheral neuropathy

          -  Understand the nature of this study and give written informed consent.

        Exclusion Criteria:

        You cannot participate in this study if any of the following apply to you:

          -  Stage IV disease

          -  History of prior malignancy within five years

          -  Women who are pregnant or breast-feeding

        Please note: There are additional inclusion/exclusion criteria. The study center will
        determine if you meet all of the criteria. If you do not qualify for the trial, study
        personnel will explain the reasons. If you do qualify, study personnel will explain the
        trial in detail and answer any questions you may have.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R. Spigel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 11, 2012</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <firstreceived_results_date>October 11, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>Patients with potentially resectable clinical stage IB, II, and selected III NSCLC received gemcitabine 1000 mg/m2 days 1, 8 and docetaxel 30 mg/m2 days 1, 8 every 21 days for 3 cycles. Patients were restaged after treatment and resected 3-6 weeks later. If patients were inoperable, had incomplete resections or N2 disease, docetaxel 20 mg/m2 and carboplatin AUC = 1.5 weekly x 7 and radiation to 63 Gy was administered</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Patients with potentially resectable clinical stage IB, II, and selected III NSCLC received gemcitabine 1000 mg/m2 days 1, 8 and docetaxel 30 mg/m2 days 1, 8 every 21 days for 3 cycles. Patients were restaged after treatment and resected 3-6 weeks later. If patients were inoperable, had incomplete resections or N2 disease, docetaxel 20 mg/m2 and carboplatin AUC = 1.5 weekly x 7 and radiation to 63 Gy was administered</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="75"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="62" lower_limit="42" upper_limit="82"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="47"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="75"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response Rate</title>
        <description>A pathological complete response (pCR) was defined as having no residual cancer at the primary site or in regional lymph nodes on pathologic review.</description>
        <time_frame>18 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients who underwent a thoracotomy were assigned a pathologic response category.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients with potentially resectable clinical stage IB, II, and selected III NSCLC received gemcitabine 1000 mg/m2 days 1, 8 and docetaxel 30 mg/m2 days 1, 8 every 21 days for 3 cycles. Patients were restaged after treatment and resected 3-6 weeks later. If patients were inoperable, had incomplete resections or N2 disease, docetaxel 20 mg/m2 and carboplatin AUC = 1.5 weekly x 7 and radiation to 63 Gy was administered</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pathologic Complete Response Rate</title>
            <description>A pathological complete response (pCR) was defined as having no residual cancer at the primary site or in regional lymph nodes on pathologic review.</description>
            <units>Percent of participants with pCR</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Progression-free survival was calculated as the elapsed time between the date of study registration and the date of recurrence or death from any cause.</description>
        <time_frame>19 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients were assessed for progression free survival after a median follow up of 19 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients with potentially resectable clinical stage IB, II, and selected III NSCLC received gemcitabine 1000 mg/m2 days 1, 8 and docetaxel 30 mg/m2 days 1, 8 every 21 days for 3 cycles. Patients were restaged after treatment and resected 3-6 weeks later. If patients were inoperable, had incomplete resections or N2 disease, docetaxel 20 mg/m2 and carboplatin AUC = 1.5 weekly x 7 and radiation to 63 Gy was administered.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progression Free Survival (PFS)</title>
            <description>Progression-free survival was calculated as the elapsed time between the date of study registration and the date of recurrence or death from any cause.</description>
            <units>Months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9.9" lower_limit="5.9" upper_limit="13.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>Overall response rate is the percentage of patients with complete response or partial response per RECIST v.1 Criteria. Complete response (CR) = Disappearance of all target lesions, disappearance of all nontarget lesions for at least 4 weeks. Partial Response (PR) = At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameters.</description>
        <time_frame>18 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients who were assessable after completion of 9 weeks of treatment were evaluated and assigned a response category.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients with potentially resectable clinical stage IB, II, and selected III NSCLC received gemcitabine 1000 mg/m2 days 1, 8 and docetaxel 30 mg/m2 days 1, 8 every 21 days for 3 cycles. Patients were restaged after treatment and resected 3-6 weeks later. If patients were inoperable, had incomplete resections or N2 disease, docetaxel 20 mg/m2 and carboplatin AUC = 1.5 weekly x 7 and radiation to 63 Gy was administered</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Response Rate (ORR)</title>
            <description>Overall response rate is the percentage of patients with complete response or partial response per RECIST v.1 Criteria. Complete response (CR) = Disappearance of all target lesions, disappearance of all nontarget lesions for at least 4 weeks. Partial Response (PR) = At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameters.</description>
            <units>Percent of patients with CR or PR</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival was calculated as the elapsed time bewteen date of study registration and the date of death.</description>
        <time_frame>18 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients were assessed for overall survival after a median follow-up of 19 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients with potentially resectable clinical stage IB, II, and selected III NSCLC received gemcitabine 1000 mg/m2 days 1, 8 and docetaxel 30 mg/m2 days 1, 8 every 21 days for 3 cycles. Patients were restaged after treatment and resected 3-6 weeks later. If patients were inoperable, had incomplete resections or N2 disease, docetaxel 20 mg/m2 and carboplatin AUC = 1.5 weekly x 7 and radiation to 63 Gy was administered</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Survival (OS)</title>
            <description>Overall survival was calculated as the elapsed time bewteen date of study registration and the date of death.</description>
            <units>Months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18" lower_limit="14.8" upper_limit="21.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Patients with potentially resectable clinical stage IB, II, and selected III NSCLC received gemcitabine 1000 mg/m2 days 1, 8 and docetaxel 30 mg/m2 days 1, 8 every 21 days for 3 cycles. Patients were restaged after treatment and resected 3-6 weeks later. If patients were inoperable, had incomplete resections or N2 disease, docetaxel 20 mg/m2 and carboplatin AUC = 1.5 weekly x 7 and radiation to 63 Gy was administered</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac General – Other (Coronary Artery Disease)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Obstruction, GI – Bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term (Death NOS)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term (Disease Progression NOS)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Infection – Other (bronchitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC – Lung (pnemonia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Lung (pnemonia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome (ARDS)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other (Acute respiratory failure)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other (Chronic Obstructive Pulmonary Disease)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Intra-operative injury – Heart</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Radiation esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Taste Alteration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain (NOS)</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - joint</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain - muscles</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy - sensory</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration - anxiety</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pulmonary Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review/embargo results communications prior to public release for a period that is &gt;60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Hainsworth, MD</name_or_title>
      <organization>Sarah Cannon Research Institute</organization>
      <phone>1-877-691-7274</phone>
      <email>ASKSARAH@scresearch.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
